Late-breaking study results reported at ECTRIMS 2013 indicate that neurofilament levels may be reliable biomarkers of nerve damage and disease progression in patients with relapsing multiple sclerosis.
Study results show that treatment with riluzole did not slow the rate of brain atrophy and did not demonstrate a detectable neuroprotective effect in patients with early RRMS.
Patients treated with oromucosal nabiximols spray experienced up to 30% reduction in spasticity, as measured by a numerical rating scale, after 12 months of treatment.
Nonadherence is highest in patients undergoing treatment with subcutaneous or intramuscular injection formulations of DMT.
Clinicians can use the MSPT, an iPad-based neurological performance test that simulates and extends the Multiple Sclerosis Functional Composite, to measure motor and visual function in patients with multiple sclerosis.
Patients with relapsing-remitting multiple sclerosis treated for two years with alemtuzumab demonstrated improved disease-related disability scores compared to patients who received treatment with subcutaneous interferon beta-1a.
Study results show that hip flexion weakness and, to a lesser extent, ankle dorsiflexion weakness have the greatest impact upon changes in walking speed as MS progresses
Data indicate patients with relapsing remitting multiple sclerosis (RRMS) treated with BG-12 (dimethyl fumarate) showed no clinical disease activity for up to two years.
Researchers reported the MMRV and separately administered MMR plus varicella vaccines were associated with a greater incidence of fever, seizures, and immune thrombocytopenia purpura seven to 10 days after vaccine administration.
The expected increase in high-deductible health plan (HDHP) enrollment due to implementation of the Affordable Care Act (ACA) highlights the need for more research into the health impact of HDHPs.